Live tape
Top 8, mentions 7d14,067GOOGL2,818 mentions▲ +0.04NVDA2,137 mentions▲ +0.05AMD1,932 mentions▲ +0.08QQQ1,724 mentions▲ +0.05AAPL1,715 mentions▲ +0.05SPY1,520 mentions▲ +0.06TSLA1,150 mentions▲ +0.06SPCX1,071 mentions▲ +0.05

Equity · Healthcare

CPRX

NASDAQ

Catalyst Pharmaceuticals (CPRX)

31.49 USD −0.06% vs prior close
Catalyst Pharmaceuticals, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for CPRX to draw a line in its place.

Track this symbol on TradingView
Market cap
3.9B USD
P/E (TTM)
17.7
Revenue, year to Dec 2025
589.0M USD
EPS, diluted, year to Dec 2025
1.68 USD
52-week range
19.12 USD – 31.51 USD
Avg volume
367.4K

as of Jul 14, 2026

Have Catalyst Pharmaceuticals (CPRX) insiders bought or sold shares recently?

CPRX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 15 July 2026.

Form 4

Have Catalyst Pharmaceuticals (CPRX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
12 Dec 2025Harper MollySell26,746622K USD
26 Nov 2025Del Carmen JeffreyChief Commercial OfficerSell10,983256K USD
12 Nov 2025Elsbernd BrianChief Compliance/Legal OfficerSell40,000908K USD
Sold3 open-market sales77,729$1.79M
80 other filings: grants, exercises, tax withholding and transfers, not trades
Have Catalyst Pharmaceuticals (CPRX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
15 Jul 2026Andrews William T.Chief Medical OfficerOther2,30973K USD
15 Jul 2026Daly Richard JPresident and CEOOther271,2668.5M USD
15 Jul 2026Del Carmen JeffreyChief Commercial OfficerOther14,337452K USD
15 Jul 2026DENKHAUS DONALD ADirectorOther498,77315.7M USD
15 Jul 2026Elsbernd BrianChief Legal OfficerOther242,5017.6M USD
15 Jul 2026Harper MollyDirectorOther3,694116K USD
15 Jul 2026Kalb Michael WayneChief Financial OfficerOther13,665430K USD
15 Jul 2026MCENANY PATRICK JDirectorOther4,171,559131.4M USD
15 Jul 2026Miller SteveChief Op. & Scientific OfficerOther1,093,80334.5M USD
15 Jul 2026Russo GreggChief HR OfficerOther47615K USD
15 Jul 2026Sundaram PreethiChief Strategy OfficerOther54,8041.7M USD
15 Jul 2026Thompson TamarDirectorOther3,773119K USD

Showing the 12 most recent of 80 compensation filings in this window. The figures above count all of them.

Which funds hold Catalyst Pharmaceuticals (CPRX)?

11 of the 45 institutional funds we track reported a Catalyst Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 163.7M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Catalyst Pharmaceuticals (CPRX)?
FundPositionSharesValueShares q/q
Renaissance TechnologiesHeld (±25%)2,136,07767.1M USD−9.0%
Millennium ManagementAdded1,068,72433.6M USD+39.3%
Marshall WaceAdded911,70028.7M USD+351.8%
Soros Fund ManagementNew position344,59310.8M USD
Man GroupAdded250,0007.9M USD+191.2%
Point72 Asset ManagementTrimmed176,5605.5M USD−58.5%
D. E. Shaw & Co.Added134,5314.2M USD+231.8%
Citadel AdvisorsTrimmed85,1472.7M USD−85.3%
AQR Capital ManagementTrimmed56,5971.8M USD−75.2%
Two Sigma InvestmentsNew position30,354954K USD

Showing the 10 largest of 11 reported positions. The figures above count all of them.

What has been filed or recorded for Catalyst Pharmaceuticals (CPRX)?

The filings we hold for Catalyst Pharmaceuticals, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 31 Mar 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Catalyst Pharmaceuticals (CPRX)?
And
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS 0.50 USD
31 Mar 2026FinancialsTotal assets1.1B USDat period end
31 Mar 2026FinancialsTotal equity1.0B USDat period end
31 Dec 2025Annual reportFY 2025 reportedEPS 1.68 USD
31 Dec 2025FinancialsRevenue589.0M USDfiscal year
31 Dec 2025FinancialsNet income214.3M USDfiscal year
31 Dec 2025FinancialsDiluted EPS1.68 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS 0.42 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS 0.41 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS 0.45 USD
31 Dec 2024Annual reportFY 2024 reportedEPS 1.31 USD
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS 0.35 USD
30 Jun 2024Quarterly earningsQ2 2024 reportedEPS 0.33 USD

Catalyst Pharmaceuticals (CPRX): frequently asked questions

From live data
3.9B

What is Catalyst Pharmaceuticals’ market cap?

Catalyst Pharmaceuticals is worth 3.9B USD by market value as of 14 Jul 2026, which is the share price times the shares on issue from its SEC filings.

17.7

What is Catalyst Pharmaceuticals’ P/E ratio?

Catalyst Pharmaceuticals has a price-to-earnings ratio of 17.7, as of 14 Jul 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.

589.0M

What is Catalyst Pharmaceuticals’ revenue?

Catalyst Pharmaceuticals reported revenue of 589.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Catalyst Pharmaceuticals insiders bought or sold shares recently?

No Catalyst Pharmaceuticals insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 15 Jul 2026 (SEC Form 4). See Insiders

11 of 45

Which funds own Catalyst Pharmaceuticals?

11 of the 45 funds we track reported a Catalyst Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Millennium Management and Marshall Wace. See Funds

0.50

When did Catalyst Pharmaceuticals last report earnings?

Catalyst Pharmaceuticals last reported earnings on 31 Mar 2026 for Q1 2026, with EPS of 0.50 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SEC EDGARXBRL company facts, latest period ended 31 Mar 2026
  6. SEC EDGARreported earnings figures and scheduled report dates
  7. SEC EDGARValuation computed from SEC EDGAR filings